 The FDA has accepted for review ObsEva SAs NASDAQ: OBSV marketing application for linzagolix to manage heavy menstrual bleeding associated with uterine fibroids in premenopausal women. The submission is based on data from the two Phase 3 PRIMROSE trials. 